Critically ill children are susceptible to nosocomial infections, which contribute to adverse outcomes. Deficiencies in the innate immunity lectin pathway of complement activation are implicated in a ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) ...
“We believe that the lectin pathway plays a critical role in brain injury as evidenced by our published data showing that Omeros’ MASP-2 inhibitor OMS721 significantly reduced brain infarct size and ...
Figure 1: Mannose-binding lectin (blue strands) can bind to sites on the SARS-Cov-2 spike protein on the cell membrane. One of the most striking features of the SARS-CoV-2 pandemic is that across all ...
Immunoglobulin A (IgA) nephropathy is the most prevalent glomerulonephritis worldwide that does not have a specific treatment. Its pathogenesis is complex and not well understood, but there is ...
Researchers have now discovered an important mechanism behind one of our most fundamental lines of immune function. Researchers from Aarhus University, Denmark, have now discovered an important ...
A new drug called Narsoplimab is showing early promise as a treatment for patients with severe COVID-19. Narsoplimab is produced by Omeros, a pharmaceutical company headquartered in Seattle. NIH ...
Shares of Omeros Corp. (NASDAQ:OMER) jumped 50.9% to $21.32 on Aug. 10 after it reported that six critically ill COVID-19 patients treated with its investigational lectin-pathway inhibitor, ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback